Mereo BioPharma Group (MREO)
Mereo BioPharma Group on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
3.2M
Short interest
settlement 2026-10-15
2.6
Days to cover
+1.4 days vs prior
55.9%
Short share of volume
2026-11-02
64,999
Fails to deliver
settlement 2026-10-13
Mon 9 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MREO is 3,229,718 shares, up 153,791 shares over the last month. Over the last 48 readings it ranged from 2,678,406 shares (30 September 2026) to 14,093,360 shares (13 February 2026). The latest reading sits at the bottom of that range. At the reported average volume of 1.2M shares a day that is 2.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mreo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,229,718 | +20.6% | 1,218,087 | 2.65 |
| 2026-09-30 | 2,678,406 | -12.9% | 2,142,878 | 1.25 |
| 2026-09-15 | 3,075,927 | -18.3% | 1,566,549 | 1.96 |
| 2026-08-31 | 3,764,977 | -12.8% | 1,101,379 | 3.42 |
| 2026-08-14 | 4,316,265 | +26.4% | 17,702,033 | 1.00 |
| 2026-07-31 | 3,413,324 | -3.5% | 1,015,887 | 3.36 |
| 2026-07-15 | 3,535,905 | -39.9% | 1,096,197 | 3.23 |
| 2026-06-30 | 5,883,564 | +10.0% | 1,851,783 | 3.18 |
| 2026-06-15 | 5,347,606 | -34.5% | 3,448,314 | 1.55 |
| 2026-05-29 | 8,160,044 | +43.6% | 11,050,210 | 1.00 |
| 2026-05-15 | 5,683,903 | -12.7% | 1,812,698 | 3.14 |
| 2026-04-30 | 6,508,278 | -21.3% | 1,473,737 | 4.42 |
| 2026-04-15 | 8,267,481 | -24.2% | 1,709,361 | 4.84 |
| 2026-03-31 | 10,907,448 | -3.1% | 1,416,670 | 7.70 |
| 2026-03-13 | 11,262,015 | -18.2% | 1,433,891 | 7.85 |
| 2026-02-27 | 13,764,845 | -2.3% | 2,560,589 | 5.38 |
| 2026-02-13 | 14,093,360 | +8.1% | 3,595,320 | 3.92 |
| 2026-01-30 | 13,042,775 | +32.9% | 8,676,296 | 1.50 |
| 2026-01-15 | 9,814,341 | -6.7% | 36,014,698 | 1.00 |
| 2025-12-31 | 10,517,934 | +7.5% | 34,324,222 | 1.00 |
| 2025-12-15 | 9,785,445 | +6.3% | 2,921,301 | 3.35 |
| 2025-11-28 | 9,207,930 | -0.5% | 1,274,555 | 7.22 |
| 2025-11-14 | 9,249,501 | -8.6% | 1,437,236 | 6.44 |
| 2025-10-31 | 10,121,542 | -9.3% | 1,653,871 | 6.12 |
| 2025-10-15 | 11,162,287 | -3.5% | 1,478,268 | 7.55 |
| 2025-09-30 | 11,561,612 | +4.7% | 1,081,428 | 10.69 |
| 2025-09-15 | 11,042,078 | -2.2% | 1,006,452 | 10.97 |
| 2025-08-29 | 11,292,464 | +7.6% | 891,072 | 12.67 |
| 2025-08-15 | 10,490,546 | -0.6% | 1,611,232 | 6.51 |
| 2025-07-31 | 10,548,318 | +7.2% | 2,088,792 | 5.05 |
| 2025-07-15 | 9,844,743 | +20.1% | 6,559,916 | 1.50 |
| 2025-06-30 | 8,199,011 | +3.0% | 1,171,340 | 7.00 |
| 2025-06-13 | 7,959,288 | -5.5% | 1,580,277 | 5.04 |
| 2025-05-30 | 8,422,483 | +5.9% | 788,543 | 10.68 |
| 2025-05-15 | 7,951,550 | +4.4% | 1,049,741 | 7.57 |
| 2025-04-30 | 7,613,450 | +15.4% | 1,982,502 | 3.84 |
| 2025-04-15 | 6,597,120 | +0.8% | 1,842,849 | 3.58 |
| 2025-03-31 | 6,544,993 | +8.6% | 1,062,704 | 6.16 |
| 2025-03-14 | 6,026,904 | -5.2% | 1,478,125 | 4.08 |
| 2025-02-28 | 6,360,249 | -12.4% | 1,733,875 | 3.67 |
| 2025-02-14 | 7,260,518 | +6.5% | 694,162 | 10.46 |
| 2025-01-31 | 6,820,377 | -5.3% | 1,187,195 | 5.74 |
| 2025-01-15 | 7,202,728 | -10.3% | 1,420,434 | 5.07 |
| 2024-12-31 | 8,032,628 | +13.9% | 1,185,413 | 6.78 |
| 2024-12-13 | 7,053,392 | +6.4% | 664,315 | 10.62 |
| 2024-11-29 | 6,631,324 | +17.7% | 903,046 | 7.34 |
| 2024-11-15 | 5,634,864 | +23.4% | 796,827 | 7.07 |
| 2024-10-31 | 4,565,429 | -11.5% | 535,803 | 8.52 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of MREO volume is 55.9%, up 31.9 points over the last five sessions. Over the last 30 readings it ranged from 23.9% (26 October 2026) to 76.3% (7 October 2026). The latest reading is 8.7 points above the 30-session average of 47.1%, on 195K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 109K | 195K | 55.9% | 0 |
| 2026-10-30 | 129K | 332K | 38.9% | 700 |
| 2026-10-29 | 142K | 426K | 33.4% | 0 |
| 2026-10-28 | 25K | 58K | 42.9% | 0 |
| 2026-10-27 | 87K | 184K | 47.4% | 0 |
| 2026-10-26 | 53K | 221K | 23.9% | 0 |
| 2026-10-23 | 230K | 318K | 72.3% | 548 |
| 2026-10-22 | 94K | 155K | 60.9% | 16,000 |
| 2026-10-21 | 184K | 247K | 74.5% | 0 |
| 2026-10-20 | 154K | 335K | 46.1% | 20,590 |
| 2026-10-19 | 191K | 361K | 52.9% | 10,200 |
| 2026-10-16 | 279K | 548K | 50.8% | 0 |
| 2026-10-15 | 160K | 310K | 51.6% | 5,537 |
| 2026-10-14 | 363K | 582K | 62.3% | 0 |
| 2026-10-13 | 366K | 860K | 42.6% | 58,848 |
| 2026-10-12 | 442K | 948K | 46.6% | 12,300 |
| 2026-10-09 | 465K | 845K | 55.0% | 0 |
| 2026-10-08 | 306K | 502K | 61.0% | 104 |
| 2026-10-07 | 547K | 718K | 76.3% | 0 |
| 2026-10-06 | 200K | 773K | 25.9% | 0 |
| 2026-10-05 | 808K | 1.5M | 52.2% | 2,436 |
| 2026-10-02 | 230K | 615K | 37.5% | 0 |
| 2026-10-01 | 340K | 1.0M | 32.6% | 0 |
| 2026-09-30 | 1.1M | 2.1M | 52.0% | 75 |
| 2026-09-29 | 451K | 1.3M | 35.1% | 10,100 |
| 2026-09-28 | 536K | 1.1M | 47.8% | 5 |
| 2026-09-25 | 465K | 1.5M | 31.1% | 0 |
| 2026-09-24 | 215K | 821K | 26.2% | 18,715 |
| 2026-09-23 | 1.2M | 2.6M | 46.9% | 32,709 |
| 2026-09-22 | 413K | 1.3M | 31.7% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in MREO is 64,999 shares, up 43,999 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (2 September 2026) to 512,384 shares (8 May 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 64,999 | $0.32 | $21K |
| 2026-10-06 | 21,000 | $0.39 | $8K |
| 2026-09-30 | 35,579 | $0.37 | $13K |
| 2026-09-29 | 17,800 | $0.37 | $7K |
| 2026-09-22 | 97,428 | $0.29 | $28K |
| 2026-09-21 | 107,319 | $0.30 | $32K |
| 2026-09-08 | 776 | $0.25 | $194 |
| 2026-09-02 | 3 | $0.28 | $1 |
| 2026-08-31 | 54,916 | $0.25 | $14K |
| 2026-08-27 | 14,044 | $0.28 | $4K |
| 2026-08-26 | 39,934 | $0.28 | $11K |
| 2026-08-21 | 10 | $0.29 | $3 |
| 2026-08-14 | 14 | $0.31 | $4 |
| 2026-08-11 | 23 | $0.27 | $6 |
| 2026-08-07 | 34 | $0.30 | $10 |
| 2026-07-24 | 50 | $0.29 | $15 |
| 2026-07-15 | 85 | $0.31 | $26 |
| 2026-07-14 | 810 | $0.32 | $259 |
| 2026-07-02 | 3,065 | $0.32 | $981 |
| 2026-06-25 | 87,818 | $0.30 | $26K |
| 2026-06-15 | 23,476 | $0.31 | $7K |
| 2026-06-12 | 20,297 | $0.31 | $6K |
| 2026-06-04 | 59,864 | $0.33 | $20K |
| 2026-06-03 | 4,989 | $0.34 | $2K |
| 2026-05-27 | 93,396 | $0.33 | $31K |
| 2026-05-19 | 31,119 | $0.24 | $7K |
| 2026-05-14 | 100 | $0.26 | $26 |
| 2026-05-08 | 512,384 | $0.24 | $123K |
| 2026-05-07 | 5,821 | $0.24 | $1K |
| 2026-04-17 | 443,759 | $0.33 | $146K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for MREO in the last 90 days. The most recent filings are listed below. Latest filing: Hughes-Wilson Alexandra (See Remarks) on 2024-09-13.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2024-09-13 | Hughes-Wilson Alexandra | See Remarks | Sell | 16K | $4.22 | $69K | 134K |
| 2024-09-13 | Hughes-Wilson Alexandra | See Remarks | Sell | 84K | $4.22 | $355K | 50K |
| 2024-09-13 | Fox Christine Ann | Chief Financial Officer | Sell | 19K | $4.22 | $81K | 89K |
| 2024-09-13 | Sermon Charles | General Counsel | Sell | 21K | $4.22 | $88K | 219K |
| 2024-09-13 | Lewicki John A. | Chief Scientific Officer | Sell | 11K | $4.22 | $46K | 79K |
| 2024-09-13 | Scots-Knight Denise | Chief Executive Officer | Sell | 60K | $4.22 | $253K | 809K |
| 2024-09-12 | Hughes-Wilson Alexandra | See Remarks | Sell | 8K | $4.47 | $35K | 191K |
| 2024-09-12 | Hughes-Wilson Alexandra | See Remarks | Sell | 40K | $4.47 | $179K | 151K |
| 2024-09-12 | Fox Christine Ann | Chief Financial Officer | Sell | 9K | $4.47 | $41K | 108K |
| 2024-09-12 | Sermon Charles | General Counsel | Sell | 10K | $4.47 | $45K | 240K |
| 2024-09-12 | Lewicki John A. | Chief Scientific Officer | Sell | 5K | $4.47 | $23K | 90K |
| 2024-09-12 | Scots-Knight Denise | Chief Executive Officer | Sell | 29K | $4.47 | $128K | 869K |
| 2024-09-11 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 75K | $1.01 | $76K | 243K |
| 2024-09-11 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 40K | $0.00 | $0 | 75K |
| 2024-09-11 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 93K | $1.40 | $131K | 168K |
| 2024-09-11 | Scots-Knight Denise | Chief Executive Officer | Exercise or conversion | 188K | $0.00 | $0 | 898K |
| 2024-09-11 | Lewicki John A. | Chief Scientific Officer | Exercise or conversion | 46K | $0.00 | $0 | 95K |
| 2024-09-11 | Fox Christine Ann | Chief Financial Officer | Exercise or conversion | 60K | $0.00 | $0 | 118K |
| 2024-09-11 | Sermon Charles | General Counsel | Exercise or conversion | 66K | $0.00 | $0 | 250K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 2K | $3.00 | $5K | 2K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Sell | 105K | $4.43 | $466K | 0 |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 6K | $1.84 | $12K | 8K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 39K | $1.31 | $51K | 60K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 12K | $2.72 | $34K | 21K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 2K | $3.87 | $8K | 105K |
| 2024-08-22 | PAKIANATHAN DEEPIKA | Director | Exercise or conversion | 43K | $0.94 | $41K | 103K |
| 2024-06-26 | Hughes-Wilson Alexandra | See Remarks | Sell | 23K | $3.39 | $78K | 35K |
| 2024-06-26 | Scots-Knight Denise | Chief Executive Officer | Sell | 92K | $3.39 | $313K | 710K |
| 2024-06-26 | Fox Christine Ann | Chief Financial Officer | Sell | 29K | $3.39 | $100K | 58K |
| 2024-06-26 | Lewicki John A. | Chief Scientific Officer | Sell | 17K | $3.39 | $57K | 49K |
| 2024-06-26 | Sermon Charles | General Counsel | Sell | 32K | $3.39 | $109K | 184K |
| 2024-06-25 | Hughes-Wilson Alexandra | See Remarks | Sell | 10K | $3.69 | $37K | 58K |
| 2024-06-25 | Scots-Knight Denise | Chief Executive Officer | Sell | 41K | $3.69 | $150K | 802K |
| 2024-06-25 | Fox Christine Ann | Chief Financial Officer | Sell | 13K | $3.69 | $48K | 87K |
| 2024-06-25 | Lewicki John A. | Chief Scientific Officer | Sell | 7K | $3.69 | $27K | 66K |
| 2024-06-25 | Sermon Charles | General Counsel | Sell | 14K | $3.69 | $52K | 217K |
| 2024-06-21 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 60K | $0.00 | $0 | 68K |
| 2024-06-21 | Fox Christine Ann | Chief Financial Officer | Exercise or conversion | 90K | $0.00 | $0 | 100K |
| 2024-06-21 | Sermon Charles | General Counsel | Exercise or conversion | 98K | $0.00 | $0 | 231K |
| 2024-06-21 | Scots-Knight Denise | Chief Executive Officer | Exercise or conversion | 282K | $0.00 | $0 | 843K |
| 2024-06-21 | Lewicki John A. | Chief Scientific Officer | Exercise or conversion | 69K | $0.00 | $0 | 73K |
| 2024-06-17 | Bender Jeremy | Director | Grant | 13K | $3.99 | $50K | 13K |
| 2024-06-17 | WYZGA MICHAEL S | Director | Grant | 25K | $3.99 | $100K | 25K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Sell | 50K | $2.94 | $147K | 33K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 75K | $1.01 | $76K | 83K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Tax withholding | 43K | $1.40 | $60K | 8K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Sell | 50K | $2.99 | $151K | 59K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Exercise or conversion | 93K | $1.40 | $131K | 101K |
| 2024-05-22 | Hughes-Wilson Alexandra | See Remarks | Tax withholding | 25K | $1.01 | $25K | 8K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of MREO in their latest filing, all on Schedule 13G (passive). The largest reported stake is Janus Henderson Biotech Innovation Master Fund Ltd at 8.7% of the class (13,759,885 shares), filed 2025-11-14 for an event on 2025-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-28 | 13G/Ano. 1 | BANK OF AMERICA CORP /DE/parent holding company | 26.9M | 3.4% | 2026-09-30 |
| 2026-08-14 | 13G/Ano. 2 | EcoR1 Capital, LLCinvestment adviser, other entity | 5.0M | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Oleg Nodelmanparent holding company, individual | 5.0M | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | EcoR1 Capital Fund Qualified, L.P.partnership | 4.7M | 0.6% | 2026-06-30 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures GP, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures II, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures II GP, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | NPV Listed, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Northpond Ventures, LLCother entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Michael P. Rubinindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 7 | JANUS HENDERSON GROUP PLCparent holding company | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences Public Fund, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLSP, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLSP, L.L.C.other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences X, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS X, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS X, L.L.C.other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Frazier Life Sciences XI, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XI, L.P.partnership | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | FHMLS XI, L.L.C.other entity | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | James N. Topperindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | Patrick J. Heronindividual | 0 | 0.0% | 2025-12-31 |
| 2026-01-06 | 13G | 683 Capital Management, LLCinvestment adviser | 65.1M | 8.2% | 2025-12-29 |
| 2026-01-06 | 13G | 683 Capital Partners, LPpartnership | 65.1M | 8.2% | 2025-12-29 |
| 2026-01-06 | 13G | Ari Zweimanindividual | 65.1M | 8.2% | 2025-12-29 |
| 2025-11-14 | 13G/Ano. 6 | Janus Henderson Biotech Innovation Master Fund Ltdinvestment company | 13.8M | 8.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Mangrove Partners IM, LLCinvestment adviser, other entity | 39.0M | 4.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 1 | Nathaniel Augustparent holding company, individual | 39.0M | 4.9% | 2025-09-30 |
13F holders
Tracked managers holding MREO at their latest 13F. JSON3 of the 30 tracked managers held MREO at their latest 13F, $577K in total at quarter-end prices. Two Sigma Investments is the largest at $419K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.3M | $419K | 0.00% | +1.1M |
| Citadel Advisors | 2026-06-30 | 444K | $141K | 0.00% | new |
| Renaissance Technologies | 2026-06-30 | 52K | $17K | 0.00% | +4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Mereo BioPharma Group in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Mereo BioPharma Group (MREO), SEC CIK 1719714, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-28.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2024-09-13.JSON and CSV
- Company record
- EDGAR filing index for CIK 1719714Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of MREO is sold short?
3,229,718 shares were held short at the 2026-10-15 settlement, 2.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MREO's daily short volume?
On 2026-11-02, 108,868 of the 194,916 MREO shares reported to FINRA were sold short, 55.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MREO have fails to deliver?
The SEC's latest file shows 64,999 MREO shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are MREO insiders buying or selling?
No open-market insider trades were reported for MREO in the last 90 days. The most recent filings are listed below. Latest filing: Hughes-Wilson Alexandra (See Remarks) on 2024-09-13.
Who owns 5% or more of MREO?
4 holders report 5% or more of MREO in their latest filing, all on Schedule 13G (passive). The largest reported stake is Janus Henderson Biotech Innovation Master Fund Ltd at 8.7% of the class (13,759,885 shares), filed 2025-11-14 for an event on 2025-09-30.
Which tracked 13F managers own MREO?
3 of the 30 tracked 13F managers held MREO shares at their latest filing, $577K in all. The largest: Two Sigma Investments (1.3M shares, $419K), Ken Griffin's Citadel Advisors (444K shares, $141K), Renaissance Technologies (52K shares, $17K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.